Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Perindopril

Perindopril

ACE inhibitor (prodrug)

AdultACEiHTNCV Risk

Indication

HTN β€’ CV risk-reduction context β€’ CKD/proteinuria pathways (protocol-dependent)

At a glance

INDICATIONS (CORE USE)

Hypertension and cardiovascular risk-reduction contexts where ACEi therapy is indicated.

ADULT DOSE (STANDARD)

PO START low (e.g. 2–4 mg daily) and titrate with BP + labs.

MAX DOSE

Common max ~8–16 mg/day depending formulation/region.

Route

PO once-daily profile

PEDIATRIC DOSE

Not routine.

Do not miss

Must-not-miss safety points

Major warning

- Angioedema can be delayed and fatal β†’ DO NOT re-challenge any ACE inhibitor - Pregnancy is contraindicated β†’ DO NOT use

Indications

HTN-focused ACEi with same class hard-stop and lab-monitoring rules.

Primary

  • Hypertension

Secondary

  • Cardiovascular risk-reduction contexts (protocol/guideline-driven)

Dosing

STANDARD (ADULT PO)

START low and titrate only with interval creatinine/potassium checks.

ADULT DOSE

Common START 2–4 mg daily; titrate by BP and safety labs.

PEDIATRIC DOSE

N/A

MAX DOSE

Often 8–16 mg/day by formulation/guideline context.

Practical Note

Do not keep escalating dose if potassium/creatinine trend is unsafe.

Warnings

Clinical warnings

  • Angioedema can be delayed and fatal β€” DO NOT re-challenge. First-dose hypotension risk is higher with volume depletion / HF / high-renin states; correct volume before starting.

Adverse effects

  • Cough
  • hyperkalemia
  • hypotension
  • AKI trend
  • angioedema

Contraindications

  • Pregnancy
  • Prior ACE inhibitor-induced angioedema
  • Bilateral renal artery stenosis (known/suspected)
  • Baseline K+ β‰₯5.5 mmol/L

Drug interactions

  • ARB / aliskiren combination: avoid routine dual RAAS blockade (AKI, hyperkalemia, hypotension risk)
  • Potassium-sparing agents / supplements: hyperkalemia risk
  • NSAIDs β†’ ↑ AKI risk + ↓ ACEi effect β€” avoid or monitor closely
  • Diuretic preload depletion can precipitate first-dose hypotension.

Special populations

Pediatrics

Not routine.

Pregnancy

Pregnancy: contraindicated.

Lactation

specialist decision.

Renal impairment

Lower starts in CKD and strict lab surveillance after changes.

Hepatic impairment

Prodrug context; titrate clinically with lab safeguards.

Elderly

Start low, monitor orthostasis and renal response early.

Administration

PO once daily with consistent adherence.

Monitoring

  • Recheck: - Check creatinine + potassium within 1–2 weeks after initiation - Recheck creatinine + potassium within 1–2 weeks after dose increase - Check earlier if CKD, elderly, volume depletion, or interacting drugs
  • Hold if:
    - HOLD if:
    - SBP <90–100
    - K+ β‰₯5.5 mmol/L
    - creatinine rise >30% from baseline
    - symptomatic hypotension
    - STOP permanently if angioedema
  • If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

A) Mild β†’ dizziness, hypotension, fatigue B) Moderate β†’ persistent hypotension, AKI trend, hyperkalemia C) Severe β†’ refractory shock, severe hyperkalemia, respiratory compromise (e.g. angioedema context)

Immediate Actions

β€’ Airway + continuous monitoring (ABC, BP, telemetry) β€’ Hypotension β†’ IV fluids first-line β€’ Refractory hypotension β†’ early vasopressors (norepinephrine) β€’ Check potassium immediately β†’ treat per hyperkalemia protocol if elevated β€’ Stop ACE inhibitor

Antidote

- No specific antidote - Supportive care + hemodynamic stabilization - Hyperkalemia treatment β†’ calcium + insulin/dextrose + potassium-shifting protocol - Airway intervention β†’ if angioedema compromises respiration

Decontamination

β€’ Recent oral ingestion β†’ activated charcoal if protected airway and early presentation (toxicology-guided)

Escalation

- Refractory hypotension or airway compromise β†’ ICU + early vasopressors / airway team - Severe hyperkalemia / AKI β†’ nephrology + renal replacement planning if indicated

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Perindopril remains lab-driven despite once-daily convenience.

Clinical pearls

Convenient schedule does not replace early post-start lab checks.

ACE inhibitor safety

  • Creatinine/potassium trend is the safety gate for titration

Pharmacokinetics

Prodrug with sustained daily profile in routine use.

Mechanism of action

ACE inhibition with RAAS suppression and renal efferent vasodilation effect.

Common brand names

Saudi Arabia

Coversyl, Aceon, Perindopril

Global

(placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA HF, post-MI, and HTN guidance
  • KDIGO CKD and proteinuria guidance
  • FDA / SFDA product labeling

Do not miss

  • Angioedema can be delayed and fatal β†’ DO NOT re-challenge
  • Pregnancy contraindicated β†’ DO NOT use
  • First-dose hypotension risk (especially HF / volume depletion) β†’ correct volume before starting
  • Hyperkalemia risk β†’ monitor potassium early
  • Creatinine/potassium trend is the safety gate for titration